Answers are grounded in this paper and cite their sources.
Post-treatment follow-up in women with CIN3 is mandatory due to relapse in up to 15% of patients within 2 years. Standard follow-up care based on hrHPV-DNA/cytology co-testing has high sensitivity but limited specificity. The aim of our proof-of-concept case-control study was to evaluate the performance of the methylation test GynTect
No takes yet. Share an insight, caveat, or question.
Hoyer et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: